Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625793 | 0.85 | ALDH1A1 (0.34) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL29580228 | 0.85 | ALDH1A1 (0.34) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL28388635 | 0.81 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL26478900 | 0.79 | TSHR (0.38) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL14007854 | 0.76 | TSHR (0.51) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL22702010 | 0.75 | PKM (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL2032975 | 0.75 | TSHR (0.55) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL13244974 | 0.74 | BTN3A1 (0.40) | ALDH1A1 | |
| SCHEMBL26478897 | 0.74 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL10977043 | 0.74 | MEN1 (0.35) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898733-B1 | ZWITTERIONIC COPOLYMERS, COATING COMPOSITIONS, ARTICLES, AND COATING METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-21 | — | — | EP | disclosed |
| US-11634525-B2 | Zwitterionic copolymers, coating compositions, articles, and coating methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220120649-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-11237085-B2 | Ligand-functionalized substrates with enhanced binding capacity | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220025093-A1 | ZWITTERIONIC COPOLYMERS, COATING COMPOSITIONS, ARTICLES, AND COATING METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-01-27 | — | — | US | disclosed |
| US-20220025093-A1 | ZWITTERIONIC COPOLYMERS, COATING COMPOSITIONS, ARTICLES, AND COATING METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-01-27 | — | — | US | disclosed |
| EP-3898733-A2 | ZWITTERIONIC COPOLYMERS, COATING COMPOSITIONS, ARTICLES, AND COATING METHODS | 3M Innovative Properties Company (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3052556-B1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | 3M INNOVATIVE PROPERTIES CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200209123-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | 3M INNOVATIVE PROPERTIES COMPANY | 2020-07-02 | — | — | US | disclosed |
| WO-2020128732-A2 | ZWITTERIONIC COPOLYMERS, COATING COMPOSITIONS, ARTICLES, AND COATING METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020128732-A2 | ZWITTERIONIC COPOLYMERS, COATING COMPOSITIONS, ARTICLES, AND COATING METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10627326-B2 | Ligand-functionalized substrates with enhanced binding capacity | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190285523-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2019-09-19 | — | — | US | disclosed |
| US-10352835-B2 | Ligand-functionalized substrates with enhanced binding capacity | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180217035-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-08-02 | — | — | US | disclosed |
| US-9958364-B2 | Ligand functionalized substrates with enhanced binding capacity | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160231208-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2016-08-11 | — | — | US | disclosed |
| EP-3052556-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | 3M Innovative Properties Company (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050767-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11237085-B2 | Ligand-functionalized substrates with enhanced binding capacity | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
| US-10627326-B2 | Ligand-functionalized substrates with enhanced binding capacity | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
| US-20180217035-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
| US-20200209123-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
| US-20220120649-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
| US-20190285523-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
| US-10352835-B2 | Ligand-functionalized substrates with enhanced binding capacity | ILK, EPCAM, ECPAS | ALDH1A1 1616/4885CYP3A4 4148/4885CYP2C9 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.